{"product_id":"henlius-five-forces-analysis","title":"Shanghai Henlius Biotech Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eShanghai Henlius faces intense rivalry from global biopharma players, high buyer scrutiny driven by payers and hospitals, and supplier leverage for specialized biologics components—while regulatory hurdles and high capital barriers limit new entrants.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Shanghai Henlius Biotech’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius depends on specialized cell culture media and high-purity reagents where roughly 70–80% of global supply comes from a few vendors, giving suppliers strong pricing power; in 2024 single-source reagent price hikes of 8–12% raised COGS for peers by ~3–5 percentage points. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius depends on advanced single-use and stainless-steel bioreactors plus downstream purification systems that are tightly integrated into its proprietary process; replacing them can cost $5–30M per production line and take 9–18 months for installation and qualification.\u003c\/p\u003e\n\u003cp\u003eRegulatory re-validation after equipment changes—often required by NMPA, EMA, or FDA—adds months and ~$1–4M in process validation and stability studies, raising effective switching costs. \u003c\/p\u003e\n\u003cp\u003eThis technical lock-in boosts leverage for established equipment suppliers, who can sustain price premiums of 5–15% and negotiate long-term service contracts that are costly for Henlius to exit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers must meet GMP and international rules (NMPA, FDA), and only ~15–20% of Chinese CMO\/CDMOs met full FDA inspection readiness in 2024, narrowing Henlius’s options; this scarcity lets compliant suppliers charge 10–25% higher premiums and demand longer minimum volumes and stricter liability clauses, increasing COGS and supply risk for Henlius.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property on Bioprocessing Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp advanced upstream and downstream bioprocessing methods are patent-protected by a few firms thermo fisher sartorius danaher so henlius depends on licensed tech to hit biosimilar yield purity targets this raises supplier bargaining power can raise cogs or capex. in global single market was concentrating pricing among top vendors constraining sourcing alternatives.\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConcentrated patents: few owners\u003c\/li\u003e\n\u003cli\u003eDependence: licensed tech needed for yields\u003c\/li\u003e\n\u003cli\u003eMarket size 2024: ~US$4.7bn single‑use\u003c\/li\u003e\n\u003cli\u003eImpact: higher COGS, limited substitutes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Global Cold Chain Logistics Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiologics and precursors need strict cold chain control (typically 2–8°C or -70°C for mRNA), so only a few global providers (DHL Life Sciences, FedEx Thermo, Kuehne+Nagel) can guarantee integrity across 120+ countries; in 2024 these firms handled ~70% of pharma cold shipments, letting them set premium rates and rigid SLAs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh temp sensitivity: 2–8°C or -70°C for some products\u003c\/li\u003e\n\u003cli\u003eTop providers cover ~70% of global pharma cold shipments (2024)\u003c\/li\u003e\n\u003cli\u003eConcentration =\u0026gt; pricing power, strict SLAs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier dominance squeezes Henlius: concentrated reagents, costly swaps \u0026amp; long contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: 70–80% of critical reagents from few vendors, 2024 single‑use market ~US$4.7bn, top cold‑chain players handled ~70% of pharma shipments, equipment replacement $5–30M and 9–18 months, regulatory re‑validation $1–4M, compliant Chinese CMOs ~15–20% in 2024—raising COGS, long contracts, and switching costs for Henlius.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent concentration\u003c\/td\u003e\n\u003ctd\u003e70–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle‑use market\u003c\/td\u003e\n\u003ctd\u003eUS$4.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain share (top firms)\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO FDA‑ready China\u003c\/td\u003e\n\u003ctd\u003e15–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquip replace cost\/time\u003c\/td\u003e\n\u003ctd\u003e$5–30M \/ 9–18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRe‑validation cost\u003c\/td\u003e\n\u003ctd\u003e$1–4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis of Shanghai Henlius Biotech highlighting competitive rivalry, supplier and buyer power, threat of new entrants and substitutes, and identifying disruptive forces and market barriers shaping its pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-sheet Porter’s Five Forces for Shanghai Henlius—quickly spot competitive hotspots and regulatory risks to streamline R\u0026amp;D and market-entry decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Centralized Procurement Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina’s Volume-Based Procurement (VBP) boosts government bargaining power by consolidating national demand; 2024 VBP rounds cut some drug prices by up to 80%, forcing deep discounts for volume guarantees.\u003c\/p\u003e\n\u003cp\u003eFor Henlius (Shanghai Henlius Biotech), VBP means trade-offs: accept steep price cuts to secure public hospital access or focus on private channels; public market volume can exceed 50% of sales for oncology biologics.\u003c\/p\u003e\n\u003cp\u003eHenlius must negotiate to protect margins—options include value-added services, durable supply contracts, and local manufacturing scale; here’s the quick math: a 50% price cut needs \u0026gt;100% volume gain to keep revenue constant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Insurance Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInclusion of Henlius products on China’s National Reimbursement Drug List (NRDL) drives volume: NRDL-listed biologics saw a 3x average sales uplift in 2023, so listing is critical for nationwide uptake.\u003c\/p\u003e\n\u003cp\u003ePublic and private payers set patient co-pay levels and formularies, giving them leverage to steer prescribing toward lower-cost or higher-value alternatives.\u003c\/p\u003e\n\u003cp\u003eHenlius must prove superior cost-effectiveness versus originators and biosimilars; in recent provincial tendering, price gaps of 20–60% determined market share shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Group Purchasing Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cplarge hospital networks and oncology centers in china city hospitals account for of drug spend negotiate steep discounts on biologics pressuring henlius price margins.\u003e\n\u003cpformulary committees control access: in of tertiary hospitals used formal biosimilar evaluations raising entry barriers for henlius unless it offers superior cost or data.\u003e\n\u003cphigh supplier-switching ability substitution rates rose to in hospital groups leverage annual contracting and volume rebates increasing revenue volatility for henlius.\u003e\n\u003c\/phigh\u003e\u003c\/pformulary\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Price Sensitivity in Biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius’ core value is lower-cost biosimilars vs expensive reference biologics, so patients are highly price-sensitive and likely to choose cheaper options for chronic treatments.\u003c\/p\u003e\n\u003cp\u003eIf rivals match efficacy at lower prices, patient and family pressure—plus physician prescribing—pushes switching, forcing Henlius to defend share with tight pricing.\u003c\/p\u003e\n\u003cp\u003eIn 2024 China biosimilar uptake rose to ~28% by volume, cutting reference drug prices by 30–50%, so Henlius must keep margins lean to compete.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue prop: affordable biosimilars drives price sensitivity\u003c\/li\u003e\n\u003cli\u003eSwitch risk: lower-cost equals higher patient push\u003c\/li\u003e\n\u003cli\u003eMarket signal: 2024 biosimilar volume ~28% in China\u003c\/li\u003e\n\u003cli\u003eCompetitive need: 30–50% reference price cuts drive margin pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Biologic Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs more Trastuzumab and Rituximab biosimilars enter China—over 10 approved Trastuzumab biosimilars and 6 Rituximab variants by end-2024—buyers gain choice and stronger leverage over price and terms, raising customer bargaining power for Henlius.\u003c\/p\u003e\n\u003cp\u003eWith multiple suppliers, large hospitals and procurement groups negotiate discounts (often 20–50% off originator prices) and service packages, making these segments buyer-driven where price and after-sales support are decisive.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10+ Trastuzumab biosimilars (2024)\u003c\/li\u003e\n\u003cli\u003e6 Rituximab biosimilars (2024)\u003c\/li\u003e\n\u003cli\u003eTypical discounts vs originator: 20–50%\u003c\/li\u003e\n\u003cli\u003eHospitals\/procurement consortia set terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers dictate terms: 80% VBP cuts, 20–50% discounts force price-for-volume shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold strong leverage: 2024 VBP cuts up to 80% and biosimilar volume ~28%, NRDL listing gives ~3x sales uplift, top 100 hospitals = ~60% oncology spend, Trastuzumab\/Rituximab biosimilars 10+\/6+ increases choice; typical discounts 20–50% force Henlius to trade price for volume and add services\/supply guarantees to protect margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP max cut\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar volume (China)\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNRDL sales uplift\u003c\/td\u003e\n\u003ctd\u003e3x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop100 hospital share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrastuzumab\/Rituximab biosimilars\u003c\/td\u003e\n\u003ctd\u003e10+\/6+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical discounts\u003c\/td\u003e\n\u003ctd\u003e20–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eShanghai Henlius Biotech Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Shanghai Henlius Biotech you’ll receive after purchase—no placeholders, fully formatted and ready for use. The document covers supplier and buyer power, competitive rivalry, threat of substitutes, and entry barriers with evidence-based insights and concise implications. Once you buy, you’ll get instant access to this same file for download and immediate application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746922279289,"sku":"henlius-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/henlius-five-forces-analysis.png?v=1772193306","url":"https:\/\/matrixbcg.com\/products\/henlius-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}